What brexpiprazole brings to the treatments for schizophrenia in pediatric patients

Leniolisib is the first and only treatment approved in the United States for APDS, a rare primary immunodeficiency.

The final episode in our podcast series on atypical anorexia discusses fat bias in health care and its impact on diagnosis and when pushback against diagnosis happens.

Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor indicated for patients as young at 5 years to control high levels of low-density lipoprotein cholesterol (LDL-C) as a result of HoFH.

Dr. Erin Harrop discusses the necessity of understanding that eating disorders do not all look the same in every patient and how a multidisciplinary approach could be an effective way to diagnose and manage anorexia nervosa that is atypical.

Results from a recent phase 3 clinical trial demonstrated topline safety and efficacy results for tapinarof cream, 1% (VTAMA; Dermavant) as a potential treatment for atopic dermatitis in patients 2 years and older.

If approved by the FDA, this 5-in-1 investigational candidate could provide the broadest meningococcal serogroup coverage.